Bristol-myers Squibb Compnay

Seattle Genetics, Inc.

Genmab A+s

Msd International Gmbh

Seagen Inc.

Anthony Cao

Esther C W Breij

Sandra Verploegen

Shyra Gardai

Neil Josephson

Benedetto Farsaci

Oyewale O Abidoye

Leonardo Viana Nicacio

Reshma Abdulla Rangwala

Ryan Heiser

The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate

This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment

Growing community of inventors

Sammamish, WA, United States of America

Anthony Cao